))
Joan Mannick on Rapamycin Longevity Series | Turning down mTOR to young levels may be good for aging
Manage episode 395746315 series 3506087
Contenu fourni par Krister Kauppi. Tout le contenu du podcast, y compris les épisodes, les graphiques et les descriptions de podcast, est téléchargé et fourni directement par Krister Kauppi ou son partenaire de plateforme de podcast. Si vous pensez que quelqu'un utilise votre œuvre protégée sans votre autorisation, vous pouvez suivre le processus décrit ici https://fr.player.fm/legal.
Dr Joan Mannick is one of the world’s leading rapamycin and mTOR researchers in the longevity field. Joan has a background in academic medicine and is currently CEO at her own company Tornado Therapeutics where they focus on developing the next generation of mTOR inhibitors. One of the company goals is to create a mTOR inhibitor which is better than Rapamycin. Throughout the years Joan has made important discoveries in humans when it comes to finding a connection between mTOR inhibition and improvement of the aging immune system. In this podcast we are going to talk about her research, drug development, mTOR, rapamycin, rapalogs and other interesting longevity topics.
Links
Big thanks to TimePie for the research help for this episode
Rapamycin resources
Connect with Krister on:
Disclaimer: The podcast is for general information and educational purposes only and is not medical advice for you or others. The use of information and materials linked to the podcast is at the users own risk. Always consult your physician with anything you do regarding your health or medical condition.
8 episodes
Partager
